Frederick L. Baehner MD
Cytopathology, Anatomic Pathology, Clinical Pathology
Chief Medical Officer, Exact Sciences, PO. Associate Professor, University of California, San Francisco
Join to View Full Profile
1600 Divisadero StSan Francisco, CA 94143
Phone+1 415-353-7043
Fax+1 415-353-7676
Dr. Baehner is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (San Francisco)Fellowship, Hematopathology, 2002 - 2003- University of California (San Francisco)Fellowship, Cytopathology, 2001 - 2002
- University of California (San Francisco) School of MedicineFellowship, Selective Pathology, 2000 - 2001
- University of California (San Francisco)Residency, Pathology-Anatomic and Clinical, 1997 - 2001
University of Kansas School of MedicineClass of 1997
Certifications & Licensure
CA State Medical License 1999 - 2027
FL State Medical License 2012 - 2014
American Board of Pathology Anatomic Pathology & Clinical Pathology- American Board of Pathology Cytopathology
Publications & Presentations
PubMed
- Optimal systemic treatment and real-world clinical application of ctDNA in patients with metastatic HER2-mutant lung cancer.Si-Yang Liu, Tatiana Erazo, Justin Jee, Andrea Arfe, Avantika Gupta
European Journal of Cancer. 2024-10-01 - 4 citationsClinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.Joseph A Sparano, Michael Crager, Robert J Gray, Gong Tang, Jess Hoag
NEJM Evidence. 2024-08-01 - BRCA1/2 mutation carriers vs the general breast cancer population (N = 799,986): 21-gene assay-based molecular characterization.Rinat Yerushalmi, Adi Pomerantz, Ron Lewin, Shani Paluch-Shimon, Lior Soussan-Gutman
Breast Cancer Research and Treatment. 2024-07-01
Journal Articles
- 21-Gene Assay as Predictor of Chemotherapy Benefit in HER2-Negative Breast CancerEleftherios P Mamounas, Frederick L Baehner, Norman Wolmark, D Lawrence Wickerham, Nature
- Author Correction: Breast-Cancer-Specific Mortality in Patients Treated Based on the 21-Gene Assay: A SEER Population-Based StudyAnn G Schwartz, Charles F Lynch, Frederick L Baehner, Nature
Professional Memberships
- Member
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
